 |
245 Diseases |  |
389 Trials |
|
389 Trials |  |
11400 News |  |
| «12...678910111213141516...143144» |
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono
Journal: Predicting response to anti-EGFR antibody, cetuximab, therapy by monitoring receptor internalization and degradation. (Pubmed Central) - Dec 4, 2023
The predictive ability of Cetux-probe-activated fluorescence was much higher than those of EGFR expression or KRAS mutation status. The Cetux-probes may become useful tools for predicting the response to cetuximab therapy by assessing EGFR degradation.
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono
Journal, Metastases: Plasma Cetuximab Concentrations Correlate With Survival in Patients With Advanced KRAS Wild Type Colorectal Cancer. (Pubmed Central) - Dec 4, 2023
The standard cetuximab dosing regimen may not be optimal for all patients. Further pharmacokinetic studies are needed to optimize cetuximab dosing given the potential improvement in OS.
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono
Biomarker, Journal, IO biomarker: Oral immunotherapy in alpha-gal red meat allergy: Could specific IgE be a potential biomarker in monitoring management? (Pubmed Central) - Dec 4, 2023
Our study showed the long-term safety and efficacy of alpha-gal OIT. Additionally, alpha-gal sIgE seems to be a potential biomarker to monitor OIT.
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono, Kaitanni (cadonilimab) / Akesobio
New P2 trial, Metastases: Cadonilimab + FOLFOX Versus FOLFOX in the Neoadjuvant Treatment of pMMR/MSS Locally Advanced Colorectal Cancer (clinicaltrials.gov) - Dec 4, 2023
P2, N=170, Recruiting, Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Additionally, alpha-gal sIgE seems to be a potential biomarker to monitor OIT. .
- || Bavencio (avelumab) / EMD Serono, Erbitux (cetuximab) / Eli Lilly, EMD Serono
P2 data, Journal, Metastases: Protocol for the EACH trial: a multicentre phase II study evaluating the safety and antitumour activity of the combination of avelumab, an anti-PD-L1 agent, and cetuximab, as any line treatment for patients with recurrent/metastatic head and neck squamous cell cancer (HNSCC) in the UK. (Pubmed Central) - Dec 1, 2023
P2
Findings will be published in peer-reviewed journals and disseminated at conferences. NCT03494322.
- | anzurstobart (BMS-986351) / BMS, Erbitux (cetuximab) / Eli Lilly
Trial completion date, Combination therapy, Metastases: CC-95251-ST-001: A Study of CC-95251, a Monoclonal Antibody Directed Against SIRP?, in Participants With Advanced Solid and Hematologic Cancers (clinicaltrials.gov) - Nov 30, 2023
P1, N=230, Active, not recruiting, Sponsor: Celgene
NCT03494322. Trial completion date: Aug 2025 --> Aug 2024
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono
Preclinical, Journal: Monoclonal antibody cetuximab impairs matrix metalloproteinases 2 and 9, epithelial-mesenchymal transition and cell migration in feline oral squamous cell carcinoma in vitro. (Pubmed Central) - Nov 30, 2023
An in vitro scratch test also demonstrated that cetuximab delayed cell migration in SCCF3. These data suggest that cetuximab mitigates invasion and metastasis processes by impairing MMPs and epithelial-mesenchymal transition pathways in FOSCC, indicating that this monoclonal antibody may help to counteract malignant progression and improve the management of locally invasive disease.
- || D3S-001 / D3 Bio
Trial completion date, Trial primary completion date, Combination therapy, Monotherapy, Metastases: A Study of D3S 001 Monotherapy or Combination Therapy in Subjects With Advanced Solid Tumors With a KRAS p.G12C Mutation (clinicaltrials.gov) - Nov 30, 2023
P1, N=168, Recruiting, Sponsor: D3 Bio (Wuxi) Co., Ltd
- ||| Keytruda (pembrolizumab) / Merck (MSD), Erbitux (cetuximab) / Eli Lilly, magrolimab (ONO-7913) / Ono Pharma
Enrollment open, Trial initiation date, Metastases: Phase II Trial of Magrolimab and Cetuximab with Pembrolizumab or Docetaxel for Recurrent/metastatic Head Neck Squamous Cell Carcinoma (clinicaltrials.gov) - Nov 30, 2023
P2, N=57, Recruiting, Sponsor: M.D. Anderson Cancer Center
These data suggest that cetuximab mitigates invasion and metastasis processes by impairing MMPs and epithelial-mesenchymal transition pathways in FOSCC, indicating that this monoclonal antibody may help to counteract malignant progression and improve the management of locally invasive disease. Not yet recruiting --> Recruiting | Initiation date: Feb 2024 --> Nov 2023
- | Loqtorzi (toripalimab-tpzi) / Shanghai Junshi Biosci, Coherus Biosci, Erbitux (cetuximab) / Eli Lilly, EMD Serono
New P2 trial, Metastases: Neoadjuvant PD-1 Inhibitor Combined With Cetuximab and Platinum in Resectable Locally Advanced Hypopharyngeal Carcinoma (clinicaltrials.gov) - Nov 30, 2023
P2, N=32, Not yet recruiting, Sponsor: Eye & ENT Hospital of Fudan University
- | Lenvima (lenvatinib) / Eisai, Merck (MSD)
Preclinical, Journal: Lenvatinib-Loaded Poly(lactic-co-glycolic acid) Nanoparticles with Epidermal Growth Factor Receptor Antibody Conjugation as a Preclinical Approach to Therapeutically Improve Thyroid Cancer with Aggressive Behavior. (Pubmed Central) - Nov 29, 2023
Not yet recruiting --> Recruiting | Initiation date: Feb 2024 --> Nov 2023 These proof-of-concept findings suggest a promising strategy for administering TKIs in a more targeted and effective manner.
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono
Preclinical, Journal: Adjuvant Effect of Cinnamon Polyphenolic Components in Colorectal Cancer Cell Lines. (Pubmed Central) - Nov 29, 2023
The anticancer activity of these cinnamon-derived fractions, whose major components (as assessed by UPLC-HRMS analysis) are procyanidins and other flavonoids, strictly correlates with their ability to induce apoptosis in cancer cell lines through ERK activation and the mitochondrial membrane potential impairment. Due to the severe side effects of cetuximab administration, our results suggest the use of nutraceuticals based on the polyphenolic fractions of cinnamon extracts as adjuvants in the therapy of CRC.
- || Review, Journal: What We Have Learned About Combining a Ketogenic Diet and Chemoimmunotherapy: a Case Report and Review of Literature. (Pubmed Central) - Nov 29, 2023
The patient was later placed on trifluridine/tipiracil and bevacizumab concurrent with a ketogenic diet...On progression, the patient was transitioned to ipilumimab and nivolumab and continued to adhere to the ketogenic diet...In this report, we reviewed the latest literature about cellular mechanism of the ketogenic diet and the efficacy and relationship with chemotherapy and immunotherapy. We are about to open a ketogenic diet protocol at the Veterans Affairs Central California Health Care System in Fresno.
- || Review, Journal, PD(L)-1 Biomarker, IO biomarker: Unveiling Therapeutic Targets for Esophageal Cancer: A Comprehensive Review. (Pubmed Central) - Nov 28, 2023
Continued research is needed to develop effective targeted drugs with minimal side effects. This review serves as a valuable resource for clinicians and researchers dedicated to enhancing esophageal cancer treatment outcomes.
- || PF-07284892 / Pfizer
Enrollment closed, Enrollment change, Combination therapy, Metastases: PF-07284892 in Participants With Advanced Solid Tumors (clinicaltrials.gov) - Nov 28, 2023
P1, N=36, Active, not recruiting, Sponsor: Pfizer
This review serves as a valuable resource for clinicians and researchers dedicated to enhancing esophageal cancer treatment outcomes. Recruiting --> Active, not recruiting | N=196 --> 36
- || ERAS-601 / Erasca
Enrollment closed, Combination therapy, Monotherapy, Metastases: FLAGSHP-1: A Dose Escalation/Expansion Study of ERAS-601 in Patients With Advanced or Metastatic Solid Tumors (clinicaltrials.gov) - Nov 28, 2023
P1, N=200, Active, not recruiting, Sponsor: Erasca, Inc.
Recruiting --> Active, not recruiting | N=196 --> 36 Recruiting --> Active, not recruiting
- || BI 765063 / Boehringer Ingelheim, BI 836880 / Boehringer Ingelheim, ezabenlimab (BI 754091) / Boehringer Ingelheim
Enrollment change, Combination therapy, Metastases: A Study to Test Whether Different Combinations of BI 765063, Ezabenlimab, Chemotherapy, Cetuximab, and BI 836880 Help People With Head and Neck Cancer or Liver Cancer (clinicaltrials.gov) - Nov 28, 2023
P1, N=45, Recruiting, Sponsor: Boehringer Ingelheim
Recruiting --> Active, not recruiting N=150 --> 45
- || P2 data, Journal: Hepatic arterial oxaliplatin plus intravenous 5-fluorouracil and cetuximab for first-line treatment of colorectal liver metastases: A multicenter phase II trial. (Pubmed Central) - Nov 27, 2023
N=150 --> 45 HAI oxaliplatin plus systemic 5-fluorouracil and cetuximab appears highly effective in the frontline treatment of patients with unresectable CRLM and should be investigated further.
- || Avastin (bevacizumab) / Roche, Erbitux (cetuximab) / Eli Lilly, EMD Serono, Vectibix (panitumumab) / Amgen, Takeda
Review, Journal: Colorectal Cancer: Disease Process, Current Treatment Options, and Future Perspectives. (Pubmed Central) - Nov 25, 2023
However, many significant problems are still being experienced with these treatments, mainly off-target effects, toxic side effects, and the associated therapeutic failures of small molecular drugs and the rapid loss of efficacy of mAb therapies. Other novel delivery strategies continue to be investigated, including ligand-based targeting of CRC cells.
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono, Opdivo (nivolumab) / Ono Pharma, BMS
Journal, PD(L)-1 Biomarker, IO biomarker, Metastases: Weekly paclitaxel, carboplatin and cetuximab (PCE) combination followed by nivolumab for recurrent and/or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN). (Pubmed Central) - Nov 24, 2023
Other novel delivery strategies continue to be investigated, including ligand-based targeting of CRC cells. PCE followed by nivolumab shows a favorable survival outcome, representing the potential for rapid tumor response with PCE and extension of OS by the addition of nivolumab regardless of combined positive score.
- | Keytruda (pembrolizumab) / Merck (MSD), Erbitux (cetuximab) / Eli Lilly, EMD Serono
Journal, Metastases: Pembrolizumab versus methotrexate, docetaxel, or cetuximab in recurrent or metastatic head and neck squamous cell carcinoma (KEYNOTE-040): Subgroup analysis by pattern of disease recurrence. (Pubmed Central) - Nov 24, 2023
PCE followed by nivolumab shows a favorable survival outcome, representing the potential for rapid tumor response with PCE and extension of OS by the addition of nivolumab regardless of combined positive score. Pembrolizumab provided numerically longer OS and durable responses in all subgroups compared with SOC, suggesting that patients with previously treated R/M HNSCC benefit from pembrolizumab regardless of recurrence pattern.
- || Piqray (alpelisib) / Novartis, Erbitux (cetuximab) / Eli Lilly, EMD Serono
P1/2 data, Journal, Combination therapy, Metastases: A Phase 1b/2 Study of Alpelisib in Combination with Cetuximab in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma. (Pubmed Central) - Nov 23, 2023
P1/2
Pembrolizumab provided numerically longer OS and durable responses in all subgroups compared with SOC, suggesting that patients with previously treated R/M HNSCC benefit from pembrolizumab regardless of recurrence pattern. The addition of alpelisib to cetuximab did not demonstrate a PFS benefit in cetuximab-na
- | Avastin (bevacizumab) / Roche, Erbitux (cetuximab) / Eli Lilly, EMD Serono
Journal, MSi-H Biomarker: DNA Mutational Profiling in Patients With Colorectal Cancer Treated With Standard of Care Reveals Differences in Outcome and Racial Distribution of Mutations. (Pubmed Central) - Nov 22, 2023
These results can provide new tools to predict patient outcome and improve therapeutic decisions and trial participation in patient minorities. The molecular alterations identified in this study may direct biomarker-driven studies.
- | 5-fluorouracil / Generic mfg.
Retrospective data, Journal, Metastases: Triplet-drug chemotherapy combined with anti-EGFR antibody as an effective therapy for patients with initially unresectable metastatic colorectal cancer: a meta-analysis. (Pubmed Central) - Nov 22, 2023
The common grades 3 and 4 adverse events were diarrhea and neutropenia. Our findings show that triplet-drug chemotherapy (FOLFOXIRI) combined with anti-EGFR antibody (panitumumab or cetuximab) represents a very effective therapeutic combination associated with a significant ORR and R0 rection rate for patients with molecularly unselected and surgically unresectable metastatic CRC.
- | Avastin (bevacizumab) / Roche, Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial initiation date: Treatment of Relapsed/Refractory Intracranial Glioma in Patients Under 22 Years of Age (clinicaltrials.gov) - Nov 21, 2023
P1/2, N=20, Not yet recruiting, Sponsor: University of Miami
Our findings show that triplet-drug chemotherapy (FOLFOXIRI) combined with anti-EGFR antibody (panitumumab or cetuximab) represents a very effective therapeutic combination associated with a significant ORR and R0 rection rate for patients with molecularly unselected and surgically unresectable metastatic CRC. Initiation date: Dec 2023 --> Mar 2024
- || pegenzileukin (SAR444245) / Sanofi, Innovent Biologics
Trial completion date, Metastases: A Study of SAR444245 Combined With Other Anticancer Therapies for the Treatment of Participants With Gastrointestinal Cancer (Master Protocol) (Pegathor Gastrointestinal 203) (clinicaltrials.gov) - Nov 20, 2023
P2, N=280, Active, not recruiting, Sponsor: Sanofi
Initiation date: Dec 2023 --> Mar 2024 Trial completion date: Sep 2023 --> Mar 2024
- || Ibrance (palbociclib) / Pfizer, Erbitux (cetuximab) / Eli Lilly, EMD Serono
P1 data, Journal, Combination therapy, Metastases: A Phase I Study of the CDK4/6 Inhibitor, Palbociclib in Combination with Cetuximab and Radiotherapy (IMRT) for Locally Advanced Head and Neck Squamous Cell Carcinoma. (Pubmed Central) - Nov 20, 2023
P1/2
The RP2D was established, while no MTD was determined. The regimen demonstrated promising preliminary efficacy, suggesting further investigation is warranted in cisplatin-ineligible p16/HPV-unrelated LA-HNSCC patients.
- | Imbruvica (ibrutinib) / AbbVie, J&J
Phase classification, Combination therapy, Metastases: Study to Evaluate Ibrutinib Combination Therapy in Patients With Selected Gastrointestinal and Genitourinary Tumors (clinicaltrials.gov) - Nov 18, 2023
P1/2, N=263, Completed, Sponsor: Pharmacyclics LLC.
The regimen demonstrated promising preliminary efficacy, suggesting further investigation is warranted in cisplatin-ineligible p16/HPV-unrelated LA-HNSCC patients. Phase classification: P1b/2 --> P1/2
- Braftovi (encorafenib) / Ono Pharma, Pierre Fabre, Pfizer, Mektovi (binimetinib) / Ono Pharma, Pierre Fabre, Pfizer
Trial completion date, Trial primary completion date: The FLOTILLA Study: Providing Continued Access to The Study Medicines Encorafenib and Binimetinib for Participants in Prior Clinical Trials (clinicaltrials.gov) - Nov 18, 2023
P4, N=46, Recruiting, Sponsor: Pfizer
Phase classification: P1b/2 --> P1/2 Trial completion date: May 2027 --> Dec 2026 | Trial primary completion date: May 2027 --> Dec 2026
- |||||| ficlatuzumab (AV-299) / LG Chem
Enrollment open, Combination therapy, Metastases: FIERCE-HN: A Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV Negative Head and Neck Squamous Cell Carcinoma (clinicaltrials.gov) - Nov 18, 2023
P3, N=410, Recruiting, Sponsor: AVEO Pharmaceuticals, Inc.
Trial completion date: May 2027 --> Dec 2026 | Trial primary completion date: May 2027 --> Dec 2026 Not yet recruiting --> Recruiting
- || Keytruda (pembrolizumab) / Merck (MSD), Lenvima (lenvatinib) / Eisai, Merck (MSD)
Trial completion date, Trial primary completion date, Combination therapy, Monotherapy, Metastases: Lenvatinib (E7080/MK-7902) in Combination With Pembrolizumab (MK-3475) vs. Standard Chemotherapy and Lenvatinib Monotherapy in Participants With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma That Progressed After Platinum Therapy and Immunotherapy (MK-7902-009/E7080-G000-228/LEAP-009) (clinicaltrials.gov) - Nov 18, 2023
P2, N=400, Recruiting, Sponsor: Merck Sharp & Dohme LLC
Not yet recruiting --> Recruiting Trial completion date: Aug 2024 --> Feb 2027 | Trial primary completion date: Aug 2024 --> Jul 2025
- | gemcitabine / Generic mfg.
Journal: High-Load Gemcitabine Inorganic-Organic Hybrid Nanoparticles as Image-Guided Tumor-Selective Drug-Delivery System To Treat Pancreatic Cancer. (Pubmed Central) - Nov 17, 2023
GMP-IOH-NPs result in a higher anti-tumor efficacy compared to free GEM and is further enhanced applying cetuximab-functionalized GMP-CTX-IOH-NPs. By maximizing the therapeutic benefits with high drug load, tumor-specific delivery, minimizing undesired side effects, overcoming mechanisms of chemoresistance, and preventing systemic GEM inactivation, we anticipate GMP-IOH-NPs to have a high chance to significantly improve current PDAC-patient outcome.
- || Avastin (bevacizumab) / Roche, Erbitux (cetuximab) / Eli Lilly, EMD Serono, Vectibix (panitumumab) / Amgen, Takeda
Review, Journal, Metastases: Selecting Optimal First-Line Treatment for Microsatellite Stable and Non-Mutated RAS/BRAF Metastatic Colorectal Cancer. (Pubmed Central) - Nov 15, 2023
Data indicate that patients with proficient MMR, RAS/BRAF wt mCRC are candidates for an anti-EGFR antibody plus doublet chemotherapy if they have a left-sided primary tumor, or for anti-VEGF (bevacizumab) plus doublet or triplet chemotherapy if they have a right-sided primary tumor. Future studies may provide more predictive biomarkers to further personalize therapy for this heterogeneous disease.
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono
Enrollment closed, Trial primary completion date, Metastases: FIRE-4: Metastatic Colorectal Cancer (RAS-wildtype) After Response to First-line Treatment With FOLFIR Plus Cetuximab (clinicaltrials.gov) - Nov 15, 2023
P3, N=673, Active, not recruiting, Sponsor: Ludwig-Maximilians - University of Munich
Future studies may provide more predictive biomarkers to further personalize therapy for this heterogeneous disease. Recruiting --> Active, not recruiting | Trial primary completion date: Dec 2022 --> Nov 2023
- | Enweida (envafolimab) / 3DMed, Tracon Pharma, Ascletis, Erbitux (cetuximab) / Eli Lilly, EMD Serono
Enrollment closed, Metastases: CEIL: Cetuximab and Envafolimab Plus mFOLFOXIRI as First-line Treatment for RAS/BRAF Wild-type, MSS, Unresectable Left-side Metastatic Colorectal Cancer (clinicaltrials.gov) - Nov 15, 2023
P2, N=198, Active, not recruiting, Sponsor: Sun Yat-sen University
Recruiting --> Active, not recruiting | Trial primary completion date: Dec 2022 --> Nov 2023 Not yet recruiting --> Active, not recruiting
- || Erbitux (cetuximab) / Eli Lilly, EMD Serono, Vectibix (panitumumab) / Amgen, Takeda
Preclinical, Review, Journal, Metastases: Overcoming the hurdles: surmounting acquired resistance to anti-EGFR therapy in metastatic colorectal cancer. (Pubmed Central) - Nov 14, 2023
Although our understanding of primary resistance to anti-EGFR therapy has improved, acquired resistance remains a significant hurdle. This review explores the potential mechanisms underpinning this acquired resistance and strategies to overcome it.
- || Akalux (cetuximab sarotalocan) / Rakuten Medical
Review, Journal: Review of RM-1929 Near-Infrared Photoimmunotherapy Clinical Efficacy for Unresectable and/or Recurrent Head and Neck Squamous Cell Carcinoma. (Pubmed Central) - Nov 14, 2023
Low-grade postoperative localized pain and edema were the most frequently reported side effects, and preliminary reports on quality of life and pain levels suggest that RM-1929 NIR-PIT does not significantly decrease quality of life and is manageable with existing pain management strategies, including opioids. These preliminary data in real-world use of RM-1929 NIR-PIT show that it is a well-tolerated therapy that has clinically meaningful outcomes for patients with unresectable and/or recurrent HNSCC.
- | cabazitaxel / Generic mfg.
Journal: EGFR Targeted Redox Sensitive Chitosan Nanoparticles of Cabazitaxel: Dual-Targeted Cancer Therapy, Lung Distribution, and Targeting Studies by Photoacoustic and Optical Imaging. (Pubmed Central) - Nov 14, 2023
Furthermore, F-CTX-CZT-CS-SH-NPs demonstrated improved anticancer activity in the benzo(a)pyrene lung cancer model with a higher survival rate. Due to the synergistic combination of enhanced permeability and retention (EPR) effect of small-sized nanoparticles, the innovative and redox sensitive TPGS-SH moiety and the dual folate and EGFR mediated augmented endocytosis have all together significantly enhanced their biodistribution and targeting exclusively to the lung which is evident from their ultrasound/photoacoustic and in vivo imaging system (IVIS) studies.
- | Avastin (bevacizumab) / Roche, Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial primary completion date, Metastases: AIO-KRK-0116: FOLFOXIRI Plus Cetuximab vs. FOLFOXIRI Plus Bevacizumab 1st-line in BRAF-mutated mCRC (clinicaltrials.gov) - Nov 14, 2023
P2, N=109, Active, not recruiting, Sponsor: Ludwig-Maximilians - University of Munich
Due to the synergistic combination of enhanced permeability and retention (EPR) effect of small-sized nanoparticles, the innovative and redox sensitive TPGS-SH moiety and the dual folate and EGFR mediated augmented endocytosis have all together significantly enhanced their biodistribution and targeting exclusively to the lung which is evident from their ultrasound/photoacoustic and in vivo imaging system (IVIS) studies. Trial primary completion date: Nov 2022 --> Nov 2023
- || Bavencio (avelumab) / EMD Serono, Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial primary completion date: FIRE-6: FOLFIRI + Cetuximab + Avelumab RAS Wild-type CRC (clinicaltrials.gov) - Nov 14, 2023
P2, N=57, Active, not recruiting, Sponsor: Ludwig-Maximilians - University of Munich
Trial primary completion date: Nov 2022 --> Nov 2023 Trial primary completion date: Aug 2022 --> Nov 2023
- | divarasib (RG6330) / Roche
Phase classification, Combination therapy, Metastases: A Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-6036 Alone or in Combination in Participants With Advanced or Metastatic Solid Tumors With a KRAS G12C Mutation (clinicaltrials.gov) - Nov 13, 2023
P1, N=498, Recruiting, Sponsor: Genentech, Inc.
Trial primary completion date: Aug 2022 --> Nov 2023 Phase classification: P1a/1b --> P1
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono, Vectibix (panitumumab) / Amgen, Takeda
Journal: An Analysis of Risk Factors for the Development of Acneiform Eruptions in Patients on Monoclonal Antibody Epidermal Growth Factor Receptor Inhibitors. (Pubmed Central) - Nov 9, 2023
Acneiform eruptions are a common cutaneous adverse event of EGFRi therapy. Ongoing research is required to elucidate risk factors for the development of acneiform eruptions, to improve the quality of life of oncology patients.
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial completion date, Trial primary completion date: Super Selective Intra-arterial Repeated Infusion of Cetuximab (Erbitux) With Reirradiation for Treatment of Relapsed/Refractory GBM, AA, and AOA (clinicaltrials.gov) - Nov 8, 2023
P2, N=37, Recruiting, Sponsor: Northwell Health
Ongoing research is required to elucidate risk factors for the development of acneiform eruptions, to improve the quality of life of oncology patients. Trial completion date: May 2025 --> May 2026 | Trial primary completion date: May 2024 --> May 2025
- ||| NT219 / Purple Biotech
Enrollment change, Trial completion date, Trial primary completion date, Combination therapy, Metastases: A Study to Evaluate NT219 Alone and in Combination With ERBITUX (clinicaltrials.gov) - Nov 8, 2023
P1/2, N=110, Recruiting, Sponsor: TyrNovo Ltd.
Trial completion date: May 2025 --> May 2026 | Trial primary completion date: May 2024 --> May 2025 N=75 --> 110 | Trial completion date: Sep 2023 --> Sep 2024 | Trial primary completion date: Jun 2023 --> Jun 2024
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono
Journal: SLC25A21 downregulation promotes KRAS-mutant colorectal cancer progression by increasing glutamine anaplerosis. (Pubmed Central) - Nov 8, 2023
Moreover, the arrested ?-KG efflux that occurred in response to SLC25A21 depletion inhibited the activity of ?-KG-dependent DNA demethylases, resulting in a further decrease in SLC25A21 expression. Our studies demonstrate that SLC25A21 plays a significant role as a tumor suppressor in KRAS-mutant CRC by antagonizing Gln-dependent anaplerosis to limit GTP availability for KRAS activation, which suggests potential alternative therapeutic strategies for KRAS-mutant CRC.
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono
Journal: Premedication strategy in cetuximab rechallenge after Grade 2 hypersensitivity reactions. (Pubmed Central) - Nov 8, 2023
Known risk factors include male sex and the accumulation of cetuximab-specific IgE. These may be mitigated by the addition of increased premedication with dexamethasone and famotidine with concurrent reduced infusion rate.
- | Ibrance (palbociclib) / Pfizer, Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial completion date: PD 0332991 and Cetuximab in Patients With Incurable SCCHN (clinicaltrials.gov) - Nov 7, 2023
P1/2, N=96, Active, not recruiting, Sponsor: Washington University School of Medicine
These may be mitigated by the addition of increased premedication with dexamethasone and famotidine with concurrent reduced infusion rate. Trial completion date: Apr 2025 --> Oct 2024
- | PF-07799933 / Pfizer
Trial completion date, Combination therapy, Metastases: A Study to Learn About the Study Medicine Called PF-07799933 in People With Advanced Solid Tumors With BRAF Alterations. (clinicaltrials.gov) - Nov 7, 2023
P1, N=174, Recruiting, Sponsor: Pfizer
Trial completion date: Apr 2025 --> Oct 2024 Trial completion date: Apr 2027 --> Feb 2028
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono
Preclinical, Journal: Multi-kinase compensation rescues EGFR knockout in a cell line model of head and neck squamous cell carcinoma. (Pubmed Central) - Nov 6, 2023
These data offer insights into EGFR inhibitor resistance and show that resistance to EGFR knockout likely occurs through a complex network of kinases. Future studies of cetuximab-resistant HNSCC tumors are warranted to determine if this EMT phenotype and/or multi-kinase resistance is observed in patients.
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono
Journal: Increased risk of venous and arterial thromboembolism in patients with colorectal cancer receiving cetuximab-based combination chemotherapy: A population-based study in Korea. (Pubmed Central) - Nov 6, 2023
Future studies of cetuximab-resistant HNSCC tumors are warranted to determine if this EMT phenotype and/or multi-kinase resistance is observed in patients. Cetuximab with irinotecan- or oxaliplatin-based doublet chemotherapy was associated with an increased risk of any thromboembolic events, VTE, and ATE; further studies are warranted to examine the underlying mechanisms.